Navigation Links
BioMarin to Present at the Baird Growth Stock Conference
Date:5/7/2009

NOVATO, Calif., May 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Thursday, May 14, 2009 at 10:40 a.m. CT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R),
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Announces First Quarter 2009 Financial Results
2. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
3. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
4. BioMarin to Present at the 4th Annual Citi Biotech Day
5. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
6. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
7. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
8. BioMarin to Present at the Piper Jaffray Healthcare Conference
9. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
10. BioMarin to Present at the Credit Suisse Healthcare Conference
11. BioMarin Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... From cell phones to cars and flashlights, ... Scientists and technology companies constantly are seeking ways ... the first time using a water-based solution, researchers ... long-lasting and more efficient nuclear battery that could ... reliable energy source in automobiles and also in ...
(Date:9/16/2014)... CHAPEL HILL, N.C. , Sept. 16, 2014 /PRNewswire/ ... its experimental heart failure compound has been shown to ... The preclinical results demonstrate an alternative to intravenous infusions ... with HNO prodrugs. The data were presented yesterday at ... Annual Scientific Meeting in Las Vegas ...
(Date:9/16/2014)... , Sept. 16, 2014  The Council ... entrepreneurial support organization in the country, today released ... Report . It showed that ... North Carolina startups in the technology, ... more global investment from a variety of sources. Significant ...
(Date:9/16/2014)... Convoy Therapeutics, Inc., a specialty ... to treat patients directly at the site of ... Technology Platform announced today that John Muraski, Ph.D., ... the White Hat Life Science Investor Conferenceā„¢ on ... In addition, interested individuals can meet Convoy ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... To highlight its 20 years of experience as ... ( www.microtestlabs.com ) is offering free microbial identification ... tests, to eligible attendees visiting the Microtest exhibit, #828, ... highlight Microtest,s wide range of laboratory testing and validation ...
... RGEN ) announced today that the Company ... will present at the BIO CEO and Investor Conference ... at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, ... available via Repligen,s website at www.repligen.com and ...
... Secretropin(R) , the first clinically proven natural stimulator of ... as a more desirable "first step" approach to pursuing ... Secretropin(R) is only available through ... to increase the body,s own production and release of ...
Cached Biology Technology:Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... make us sick can take up residence in and ... or other troublesome symptom, according to new research at ... , On average, healthy individuals carry about five types ... in BioMed Central Biology . The study is ... viruses in healthy people. , The research was ...
(Date:9/16/2014)... chunk of rock hit the Yukatan peninsula near the site ... 100 teratons of TNT. It left a crater more than ... and volcanism are widely accepted to have wiped out the ... But what happened to the plants on which the dinosaurs ... University of Arizona reveals that the meteorite impact that spelled ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... - Primary Energy Recycling Corporation (TSX: PRI), (the "Company") a clean energy company ... announced its financial and operational results for the first quarter ended March ... Highlights for the ... 4.3% for the three months ended March 31, 2010, ...
... Spain and the UK have identified the final piece in ... Published today by PNAS, the breakthrough discovery by the Consejo ... of East Anglia (UEA) has implications for agribusiness, the environment ... deposit which accumulates in the seeds, beans and tubers of ...
... cystic fibrosis can be caused by genetic "nonsense mutations" ... Bedwell, Ph.D., a professor in the University of Alabama ... now closer to producing drugs that will fix this ... Bedwell is a renowned researcher on the select group ...
Cached Biology News:Primary Energy Reports Improved First Quarter Results 2Primary Energy Reports Improved First Quarter Results 3Primary Energy Reports Improved First Quarter Results 4Primary Energy Reports Improved First Quarter Results 5Scientists discover final piece in phytate jigsaw 2Drug may treat cystic fibrosis, other diseases caused by 'nonsense mutations,' UAB researcher says 2